Literature DB >> 7927492

Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction.

M Paroli1, G Carloni, A Franco, G De Petrillo, E Alfani, A Perrone, V Barnaba.   

Abstract

Malignant transformation of human hepatocytes is often accompanied by an increased expression of major histocompatibility complex (MHC) molecules, but whether this phenomenon is related to an enhanced immunogenicity remains unknown. In this study, we tested the capacity of a series of human hepatoma cell lines to induce proliferation of allogeneic T cells in primary mixed lymphocyte tumour cultures (MLTC). These cell lines were positive for class I molecules, whereas class II molecule expression was either constitutive or inducible by treatment with interferon-gamma (IFN-gamma). We found that HA22T/VGH cells expressing class II molecules constitutively stimulated high proliferative responses of purified CD4+ T lymphocytes, whereas class II-negative Li7A cells stimulated CD4+ T-cell responses only when induced by treatment with IFN-gamma. HA22T/VGH and Li7A cells also exerted a significant stimulatory activity for purified CD8+ T cells whereas HepG2 cells, in which MHC class II molecules are neither constitutive IFN-gamma-inducible, were unable to induce CD4+ and CD8+ T-cell proliferative responses. Phenotypical analysis revealed that HA22T/VGH and Li7A expressed high levels of intracellular adhesion molecule-1 (ICAM-1) and experiments with blocking monoclonal antibodies (mAb) demonstrated that this molecule played a key role in mediating the co-stimulatory function of hepatoma cells. In addition, HA22T/VGH cells were found to produce mRNA for interleukin-1 (IL-1) beta and IL-6, while Li7a only produced IL-1 beta, yet both these cytokines were found to play a small part, if any, in T-cell co-activation. On the whole, these results show tht hepatoma cells expression MHC antigens and ICAM-1 are able to deliver signals necessary for activation of resting CD4+ and CD8+ T cells and suggest that they may actively participate in the anti-tumour immune response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927492      PMCID: PMC1414816     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells.

Authors:  C T Weaver; C M Hawrylowicz; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 2.  The influence of major histocompatibility complex class I antigens on tumor growth and metastasis.

Authors:  G J Hämmerling; D Klar; W Pülm; F Momburg; G Moldenhauer
Journal:  Biochim Biophys Acta       Date:  1987-11-25

3.  Expression of class I and class II major histocompatibility antigens on human hepatocellular carcinoma.

Authors:  C H Sung; C P Hu; H C Hsu; A K Ng; C K Chou; L P Ting; T S Su; S H Han; C M Chang
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes.

Authors:  N K Damle; K Klussman; G Leytze; A Aruffo; P S Linsley; J A Ledbetter
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

5.  Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells.

Authors:  K Tanaka; H Hayashi; C Hamada; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

6.  T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.

Authors:  W J Bateman; E J Jenkinson; J J Owen
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

7.  Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells.

Authors:  P G Natali; P Giacomini; A Bigotti; K Imai; M R Nicotra; A K Ng; S Ferrone
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Expression of class I and class II major histocompatibility complex antigens on human hepatocytes.

Authors:  A Franco; V Barnaba; P Natali; C Balsano; A Musca; F Balsano
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

9.  Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2.

Authors:  S Takagi; K Chen; R Schwarz; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

10.  HLA expression in human hepatocellular carcinoma.

Authors:  A C Paterson; R Sciot; M C Kew; F Callea; G M Dusheiko; V J Desmet
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

View more
  4 in total

Review 1.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

2.  HLA class I expression in primary hepatocellular carcinoma.

Authors:  Jian Huang; Mei-Ying Cai; Da-Peng Wei
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes.

Authors:  Katherine S Koch; Hyam L Leffert
Journal:  Hepat Med       Date:  2010-03

4.  HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen.

Authors:  Jonathan Filskov; Peter Andersen; Else Marie Agger; Jens Bukh
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.